Form 4: Quince Therapeutics Director Opts for Stock Options

Quince Therapeutics Director June Bray elected to receive 18,724 stock options in lieu of her 2026 annual cash retainer.

Summary

• June Bray, a Director at Quince Therapeutics, Inc. (QNCX), acquired 18,724 Director Stock Options.
• The transaction date for these options was January 2, 2026.
• The options have an exercise price of $3.00 per share.
• These options were granted in lieu of the annual director cash retainer for 2026, as per the Issuer's Outside Director Compensation Policy.
• The shares subject to the option will vest in equal quarterly installments over a one-year period, starting from the grant date.
• The expiration date for these stock options is January 2, 2036.

Sentiment

Score: 6

Explanation: Slightly positive, as a director choosing equity over cash indicates confidence and alignment with shareholder interests, though it's a routine compensation disclosure.

Positives

• A director electing to receive stock options instead of cash compensation demonstrates alignment of interests with shareholders, as their compensation becomes tied to the company's stock performance.
• The grant of options under a pre-existing compensation policy indicates a structured approach to director remuneration.

Risks

• The value of the stock options is subject to market fluctuations of Quince Therapeutics' common shares.
• If the company's stock price does not exceed the exercise price of $3.00, the options may expire worthless.

Future Outlook

The stock options granted will vest in equal quarterly installments over a one-year period, indicating a future schedule for the director to gain full ownership rights to the options.

Management Comments

• The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.

Industry Context

It is a common practice in the biotechnology and pharmaceutical industries, and broader public markets, for directors to receive a portion of their compensation in equity, such as stock options, to align their interests with those of shareholders and incentivize long-term company performance.

Comparison to Industry Standards

• The practice of granting stock options as part of director compensation is a standard industry practice across many sectors, including biotechnology, to foster alignment between directors and shareholder interests.
• Many companies, similar to Quince Therapeutics, utilize an 'Outside Director Compensation Policy' to formalize and standardize equity grants and cash retainers for non-employee directors, ensuring transparency and adherence to corporate governance best practices.

Corporate Governance

Related Party Transactions

• The grant of stock options to June Bray, a director, constitutes a related party transaction as it involves compensation provided by the issuer to a member of its board of directors.

Stakeholder Impact

• Shareholders: The decision by a director to take equity compensation aligns their financial interests with those of shareholders, potentially fostering a greater focus on long-term stock performance.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The stock options will vest in equal quarterly installments over a one-year period following the grant date of January 2, 2026.

Key Dates

Keywords

Quince Therapeutics, QNCX, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Compensation, Corporate Governance